ASN Asian Mineral Resources Ltd

ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX:PFSCF) ("ProMetic" or the
"Corporation") today reported revenues of $5.1 million and $20.6 million for the
quarter and year ended December 31, 2013 respectively. This compares to revenues
of $8.3 million and $23.3 million for the quarter and year ended December 31,
2012 respectively. 


"The strengthening of our market capitalization has allowed us to make the
decision to develop more of our own assets ourselves to an advanced stage prior
to partnering. This means a greater portion of the future returns generated by
our high-value products and assets will remain ours. This change to the
commercialization strategy has however resulted in the short term, in lower
licensing revenues as well as an increase in spending", observed Mr. Bruce
Pritchard, ProMetic's Chief Financial Officer. "Having now improved our capital
base by receiving more than $40 million in cash inflows in 2013 from two
financing transactions and the Hepalink investment, we can now concentrate our
attention on further progressing the key corporate initiatives necessary to
build substantial value for shareholders. 


Commenting on the progress of the corporate initiatives to build substantial
value for the shareholders, Mr. Pierre Laurin, ProMetic's President and Chief
Executive Officer stated: "PBI-4050 continues to impress with new data further
supporting the use of this product in diabetic patients with chronic diseases as
well as in other rare conditions. Our objective for this year is to quickly
confirm that the positive effects observed in multiple animal models translates
to patients". 


"It has always been our goal to leverage our unique proprietary technologies and
know-how to build a company that would bring safer, cost-effective and more
convenient therapeutic products to largely underserved patient populations. The
successful operational launch of our plasma purification facility in Laval,
Quebec has brought us closer than ever to making this vision a reality", added
Mr. Laurin. 


2013 Highlights

Business Highlights  

2013 can best be summarized as the year during which ProMetic significantly
progressed in its transition towards becoming a vertically integrated, specialty
Biopharmaceutical Corporation. Accordingly, ProMetic via using its rich
therapeutic product pipeline, has positioned itself to pursue various commercial
opportunities in areas of unmet medical needs, including rare diseases and
orphan drug opportunities.   


In 2013, ProMetic: 



--  Received a $10 million strategic equity investment by Shenzhen Hepalink
    Pharmaceutical Co., LTD. in ProMetic at a premium to the market share
    price; 
    
--  Received an orphan drug designation status for its plasma purified human
    plasminogen drug by the American Food and Drug Administration ("FDA")
    for the treatment of hypoplasminogenemia, or type I plasminogen
    deficiency ("T1PD"); 
    
--  Received a $4.8 million purchase order under its ongoing supply
    agreement with Octapharma, relating to the purchase of PrioClear(TM), a
    proprietary prion capture resin incorporated into Octapharma's
    manufacturing process for its solvent/detergent treated plasma product,
    Octaplas(R); 
    
--  Selected Alpha1-Antitrypsin (AAT) as its second plasma-derived
    therapeutic to address a well-defined unmet medical need affecting an
    estimated 100,000 people in the USA alone with less than 10% treated;  
    
--  Presented new pre-clinical data at the 2013 European Respiratory Society
    ("ERS") annual congress held in Barcelona, Spain, suggesting that PBI-
    4050 offers a new therapeutic approach to Idiopathic Pulmonary Fibrosis;
    
--  Secured a $10 million loan and issued warrants in a financing
    transaction with Thomvest Seed Capital Inc. ("Thomvest"), with no
    principal or interest repayments for 5 years;  
    
--  Presented new preclinical data at the 2013 annual meeting of the
    American Association for the Study of Liver Diseases (AASLD) supporting
    the claims that PBI-4050 anti-fibrotic activity could also be used to
    address various liver conditions such as nonalcoholic steatohepatitis
    ("NASH"); 
    
--  Raised gross proceeds of $24 million through a public offering of
    26,651,400 Common Shares of the Corporation at $0.90 per share 
    
--  Presented new preclinical data at the 2013 American Society of
    Nephrology ("ASN") annual meeting demonstrating the ability of PBI-4050
    to reduce fibrosis in the kidney and overall improve the renal function
    in various animal models; 
    
--  Received a $5.1 million purchase order for the supply of affinity resin
    from an existing client, a global leader in the biotherapeutics
    industry; and 
    
--  Achieved a major corporate milestone by successfully completing the
    first commercial-scale production run at its plasma purification
    facility, ProMetic BioProduction Inc., located in Laval, Quebec. This
    production run was completed on schedule and generated better than
    expected results.



2013 Financial Results

This financial information should be read in conjunction with the Corporation's
consolidated financial statements for the year ended December 31, 2013 as well
as the Management's Discussion and Analysis dated March 25, 2014.


Total revenues for the fourth quarter of 2013, which were derived from product
sales, development services and licensing revenues, were $5.1 million. Total
revenues for the 2013 financial year were $20.6 million as compared to $23.3
million for the previous financial year. 


Revenues from the sale of goods and services totaled $18.0 million in 2013
compared to $16.9 million in 2012. 


Licensing revenues were $2.6 million in 2013 compared to $6.4 million in 2012,
representing a decrease of $3.8 million. The decrease reflects the Corporation's
decision to further invest and advance some of its clinical assets, rather than
seeking earlier licensing revenues. 


ProMetic generated a net loss of $7.5 million for the quarter ended December 31,
2013 and a net loss of $17.4 million for the 2013 financial year compared to a
net loss of $0.4 million for the previous 2012 financial year. 


Of the $17.4 million net loss incurred in 2013, a total of $8.9 million comes
from non-cash items. $5.5 million comes from the variation in fair value of the
warrant liability associated to the Thomvest financing transaction and $3.4
million represent the expense recorded as a result of stock options and
restricted stock units issued to employees and board members. 


Non rechargeable Research and Development expenses were $13.7 million in 2013
compared to $7.8 million in 2012, representing a $5.9 million increase. The
increase mainly comes from a higher level of research activities associated to
the PBI-4050 clinical program and the costs associated with the preparation of
the Laval plasma purification facility for a GMP validation. 


"Our total assets have more than doubled following the closing of the debt and
equity transactions completed in 2013. Our cash, accounts receivable and capital
assets positions have all significantly increased during the year 2013 compared
to 2012", stated Mr. Bruce Pritchard, ProMetic's Chief Financial Officer. 


Fourth Quarter and Year End 2013 Conference Call Information

ProMetic will host a conference call at 11:00am (EST) on Thursday, March 27,
2014. The telephone numbers to access the conference call are (647) 788-4922
(International) and 1-877-223-4471 (Toll-free). A replay of the call will be
available from March 27, 2014 at 1:30 p.m. until April 12, 2014. The numbers to
access the replay are 1-416-621-4642 (passcode: 17917398) and 1-800-585-8367
(passcode: 17917398). A live audio webcast of the conference call will be
available through the following: http://www.gowebcasting.com/5345


Additional Information in Respect to the Three month and Twelve month Periods
ended December 31, 2013 


ProMetic's MD&A and 2013 Financial Statements have been filed on Sedar
(www.sedar.com) and will be available on the Company's website at
www.prometic.com. 


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. A number of both the plasma-derived and small molecule
products are under development for orphan drug indications. Headquartered in
Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada,
manufacturing facilities in the UK and business development activities in the
U.S., Europe and Asia. 


Forward Looking Statements 

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward -looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations in ProMetic's Annual Information Form for the year ended December
31, 2013, under the heading "Risk and Uncertainties related to ProMetic's
business". As a result, we cannot guarantee that any forward-looking statement
will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future
events or for any other reason, unless required by applicable securities laws
and regulations. All amounts are in Canadian dollars unless indicated otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
p.laurin@prometic.com
450-781-0115


Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
450-781-0115

Grafico Azioni Asian Mineral Resources (TSXV:ASN)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Asian Mineral Resources (TSXV:ASN)
Storico
Da Giu 2023 a Giu 2024